NCT02617849进行中（未招募）2 期
A Phase II Study of Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Wilson Miller2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年5月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Overall Response Rate as assessed by RECIST 1.1 and immune-related Response Criteria
研究概览
简要总结
This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject must:
- •Be willing and able to provide written informed consent for the trial.
- •Be ≥ 18 years of age on day of signing informed consent.
- •Have histologically confirmed diagnosis of unresectable Stage III or metastatic melanoma.
- •Patients may not have a diagnosis of uveal melanoma.
- •Have measurable disease based on RECIST 1.
- •Have a tumor sample (FFPE archival or newly obtained biopsy) of a metastatic site that is available for biomarker analysis.
- •Have an ECOG of 0 or
- •Demonstrate adequate organ function as below:
- •Absolute neutrophil count (ANC) ≥1.5 x 109/L
- •Platelets ≥100 x 109/L
- •Hemoglobin ≥90 g/L (may be transfused)
- •Serum creatinine OR CrCl ≤ 1.5 X upper limit of normal (ULN) OR ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
- •Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
- •AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases
- •Albumin >2.5 mg/dL
- •International Normalized Ratio (INR) or Prothrombin Time (PT)
- •Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- •Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- •Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
- •No known active or chronic infection with HIV, Hepatitis B, or Hepatitis C.
排除标准
- •The subject must be excluded from participating in the trial if the subject:
- •Has had prior treatment for advanced unresectable or metastatic melanoma. Prior treatment with BRAF and MEK inhibitors is permitted in this setting. A washout of at least 5-half-lives (median terminal half-life) prior to the first dose of trial treatment must have elapsed.
- •Has received prior therapy with an anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
- •Has evidence of symptomatic CNS lesions as determined by the investigator. Patients with asymptomatic lesions or previously irradiated or surgically resected are eligible.
- •Has a known additional malignancy that is progressing or requires active treatment.
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg daily prednisone equivalents) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Inhaled or topical steroids, and adrenal replacement doses ≤ 10 mg prednisone equivalents are permitted.
- •Has ≥ Grade 2 peripheral neuropathy.
- •Patients with an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy is an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Patients with hypothyroidism stable on hormone replacement will not be excluded from the study.
- •Has an active infection requiring systemic therapy.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- •Has a known history of active TB (Bacillus Tuberculosis)
- •Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
研究组 & 干预措施
Pembrolizumab, Carboplatin, Paclitaxel
Experimental
Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
干预措施: Pembrolizumab (Drug)
Pembrolizumab, Carboplatin, Paclitaxel
Experimental
Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
干预措施: Carboplatin (Drug)
Pembrolizumab, Carboplatin, Paclitaxel
Experimental
Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Overall Response Rate as assessed by RECIST 1.1 and immune-related Response Criteria
时间窗: 56 months
次要结局
- Overall Survival(56 months)
- Progression Free Survival(56 months)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(56 months)
- Melanoma-associated serological markers by multiplexed array will be generated(56 months)
研究者
Wilson Miller
Medical Oncologist
Jewish General Hospital
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)Prostate Cancer MetastaticNCT05563558Fundacion Oncosur42
已完成
2 期
Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)Metastatic Breast CancerNCT03732391CORTESI LAURA22
进行中（未招募）
2 期
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)Pleural MesotheliomaNCT06155279Istituto Oncologico Veneto IRCCS41
进行中（未招募）
2 期
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal CancerMetastatic CancerColorectal CancerNCT03475004University of Colorado, Denver53
招募中
2 期
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesBrain MetastasesTumorNCT05064280M.D. Anderson Cancer Center104